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Background/aim: Fatigue is very common symptom in patients with systemic sclerosis (SSc) and adversely affects health-related quality
of life and the ability to perform daily living activities. This study aimed to determine the severity of fatigue, and its related factors, in
patients with SSc.
Materials and methods: A total of 35 patients with SSc (6 males and 29 females, mean age of 50.71 ± 10.09 years) and 35 healthy control
subjects (8 males and 27 females, mean age of 54.14 ± 9.51 years) were included in this study. The Fatigue Impact Scale for fatigue,
Modified Medical Research Council Scale for dyspnea severity, 6-Minute Walking Test for functional capacity, Health Assessment
Questionnaire Disability Index, Scleroderma Health Assessment Questionnaire and Short Form-36 Quality of Life Questionnaire for
health-related quality of life were used in the evaluation of the subjects. Furthermore, pulmonary functions, diffusion capacity, and
respiratory and peripheral muscle strength were evaluated.
Results: Of the SSc patients, 80% experienced fatigue and presented with higher total and cognitive, physical, and psychosocial subscale
fatigue scores than the healthy control subjects (P < 0.05). Moreover, the SSc patients exhibited significantly increased dyspnea severity,
impaired pulmonary function-diffusion capacity, decreased respiratory-peripheral muscle strength, reduced functional capacity, and
worsened health-related quality of life when compared to the control group (P < 0.05). Fatigue in the SSc group was significantly
associated with age, dyspnea severity, diffusion capacity, respiratory and peripheral muscle strength, functional capacity, and healthrelated quality of life (P < 0.05).
Conclusions: Along with the decrease in diffusion capacity, increase dyspnea, a decrease in both peripheral and respiratory muscle
strength, and worsening functional capacity may have an effect on increased fatigue in SSc patients. Increased fatigue can also affect the
life quality and daily life activities of a patient. Therefore, multidisciplinary approaches are recommended to evaluate and improve these
parameters in the treatment of fatigue from the early period in SSc patients.
Key words: Systemic sclerosis, fatigue severity, pulmonary function, respiratory muscle strength, health-related quality of life

1. Introduction
Systemic sclerosis (SSc) is a multisystem disease that affects
skin and internal organs via a disturbance in fibroblast
function, vascular structure, and immune cell activation,
resulting in fibrosis [1]. Due to this fibrosis, multiple
organ and systemic involvement, such as pulmonary
hypertension (PH), interstitial lung disease (ILD),
skin thickening, finger ulcers, joint abnormalities and
contractures, and kidney failure are very common. This
multisystem involvement causes worsening prognosis,
increased morbidity, and mortality in patients with SSc.
Moreover, SSc is more prevalent in early-middle age and
female sex [2,3].

Various factors, such as cardiopulmonary involvement,
osteoarticular abnormalities, and musculoskeletal
disorders associated with multisystem involvement,
in SSc may induce fatigue, pain, decreased functional
capacity, muscle strength loss, and respiratory symptoms
[4]. However, general fatigue adversely affects healthrelated quality of life and the ability to perform daily living
activities more than other symptoms. It was reported that
the level of fatigue in these patients was as high as that
of cancer patients reported in active therapy. Currently,
etiological fatigue factors and its possible mechanism in
SSc patients have not been fully elucidated, but it has been
stated that skin tightening, system involvement, symptoms
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associated with comorbid conditions, inflammatory
muscle disease, side effects of drug therapy, lifestyle, and
psychosocial factors can cause fatigue [5].
Fatigue is a multidimensional symptom that is affected by
many psychosocial, physical, and social factors. Moreover,
it has been stated that fatigue is a major symptom in many
inflammatory chronic rheumatoid diseases, including
rheumatoid arthritis (80%–93%), ankylosing spondylitis
(65%), and systemic lupus erythematous (81%), and has
been associated with pain, female sex, longer disease
duration, increased functional limitations, and depressive
symptoms [6–8]. However, the number of clinical studies
that have thoroughly investigated the frequency, features,
and correlations of fatigue in SSc patients is insufficient.
In addition, the evaluation of fatigue in the clinic is often
neglected, although it has been stated that fatigue may be
a significant source of discomfort and disability for SSc
patients [9,10].
It is believed that studies examining the severity of
fatigue and related factors in SSc are very important
because they can provide evidence-based and bettertargeted interventions during the follow-up period and
in the management of the disease for these patients.
Therefore, the first aim of this study was to determine the
severity of fatigue, and its related factors, in patients with
SSc. The second goal was to characterize fatigue severity,
dyspnea severity, pulmonary functions, diffusion capacity,
respiratory-peripheral muscle strength, functional
capacity, and health-related quality of life of the patients to
compare with a sample of healthy control subjects.
2. Patients and methods
2.1. Participants
The study included 2 groups of volunteers, comprising the
SSc group and healthy control group, with 35 participants
in each group. Patients with SSc were diagnosed according
to the American College of Rheumatology/European
League Against Rheumatism criteria by a rheumatologist
and followed-up at the Department of ImmunologyRheumatology, between 2017 and 2019 [11]. The inclusion
criteria were being between the ages of 35–65 years and
volunteering to participate to the study. The exclusion
criteria were having other diseases that may affect the results
(mental, neurological, musculoskeletal, cardiopulmonary
disease not related to SSc, acute infection) and difficulty in
walking. The patients were stable in terms of their medical
treatment and were asked to continue their medical
treatment regularly throughout the study.
The control group consisted of healthy volunteers
who were between the ages of 35–65 years who had been
recruited from the Dokuz Eylül University, Faculty of
Medicine employees. These participants did not show
evidence of any disorders and/or diseases that may have

affected the results (mental, neurological, cardiovascular,
pulmonary, musculoskeletal disease).
2.2. Assessment
The study design was cross-sectional. Age, weight, height,
body mass index (BMI), disease duration (in years),
respiratory symptoms (cough, sputum, and dyspnea,
etc.), and other involvement were recorded. Fatigue and
dyspnea severity, pulmonary function, diffusion capacity,
respiratory and peripheral muscle strength, functional
capacity, and health-related quality of life of the individuals
were evaluated, respectively. Furthermore, between the
tests, the subjects rested for 10 min to avoid test-related
fatigue.
2.2.1. Fatigue impact scale
The Fatigue Impact Scale (FIS) measures physical,
cognitive, and social influences of fatigue. It consists of
40 items and a high score indicates a high level of fatigue.
Furthermore, it consists of 3 subscales: cognitive, physical,
and psychosocial [12].
2.2.2. Modified Medical Research Council Scale
The dyspnea severity of the patients was evaluated using
the Modified Medical Research Council Scale (mMRCS).
The mMRCS questions the dyspnea severity in daily living
activities. The mMRCS contains 5 degrees (range 0–4)
and a higher score indicates a higher perceived amount of
breathing [13].
2.2.3. Pulmonary function and diffusion capacity
The pulmonary function test was applied using a Sensor
Medics Vmax 22 0.6-2B version spirometer (ERS 1993
Uptake + Zapleta, SensorMedics, Inc, Anaheim, CA, USA).
Forced vital capacity (FVC), forced expiratory volume in
1 s (FEV1), FEV1/FVC ratio, and peak expiratory flow
(PEF) values were recorded according to the American
Thoracic Society/European Respiratory Society criteria
[14]. The single breath carbon monoxide method was used
to determine the diffusion capacity for carbon monoxide
(DLCO) measurement [15].
2.2.4. Respiratory and peripheral muscle strength
An electronic mouth pressure measuring device was used
to determine the respiratory muscle strength. The maximal
inspiratory pressure (MIP) and maximal expiratory
pressure (MEP) were measured. The MIP was measured
as the residual volume upon a maximal inspiratory effort
against an occluded airway and the MEP was measured
as the total lung capacity while performing a maximal
expiratory effort against an occluded airway. The MIP
and MEP measurements were repeated 3 times, and the
maximum value achieved was recorded [16]. In order
to evaluate the muscle strength of the lower extremities,
the dominant quadriceps muscle group was determined
and the muscle strength was measured. The quadriceps
muscle function test included an isometric maximal
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voluntary contraction force test that was performed using
a Hoggan Scientific MicroFET2 Digital Dynamometer
& Manual Muscle Tester (Salt Lake City, UT, USA). Test
was performed with the patient in a sitting position with
90° hip flexion and 60° knee extension over the end of a
chair. The patients were asked to continue the maximum
isometric contraction for 5 s and the average of the
measured values was obtained by performing 3 successive
maximal contractions. Handgrip strength was measured
to roughly define the upper extremity muscle strength.
The measurement was performed using a Jamar Hydraulic
Hand Dynamometer (Patterson Medical Products,
Warrenville, IL, USA ) in a sitting position, with shoulder
adduction and neutral rotation, elbow at 90° flexion,
forearm in mid rotation and supported, and wrist in the
neutral position. For the dominant hand, 3 measurements
were made by giving 1-min intervals between each
measurement, and the mean was recorded [17,18].
2.2.5. Functional capacity
The functional capacity of the patients was evaluated using
the 6-Minute Walking Test (6MWT). For the 6MWT, all
of the patients were asked to walk as fast as possible for 6
min down a flat, 30-m-long corridor. The total distance,
in meters, was recorded. The predicted walking distance
value for each patient was calculated by means of the
equations formulated by Enright et al., as recommended
by the American Thoracic Society. For the safety of the
patients, before and after the tests, their heart rates, blood
pressure, and oxygen saturation were checked [19].
2.2.6. Health-related quality of life
The Health Assessment Questionnaire Disability Index
(HAQ-DI), Scleroderma Health Assessment Questionnaire
(SHAQ), and Short Form-36 Quality of Life Questionnaire
(SF-36) were used for assessment of health-related quality
of life.
The HAQ-DI measures disability, function, and quality
of life using 8 functional domains of physical capacity
(dressing and grooming, arising, eating, walking, hygiene,
reach, grip, and common daily activities), which consist
of 20 items. Each item is scored between 0 (without any
difficulty) and 3 (unable to do). The SHAQ also has a
visual analogue scale (VAS) of 5 SSc symptoms and signs
(Raynaud’s phenomenon, digital ulcers, gastrointestinal
problems, pulmonary problems, and global assessment of
the severity of the disease). The SHAQ-global score was
calculated by adding the 5 SSc-related VAS symptoms
to the 8 HAQ-DI domains and dividing the sum by 13
[20,21]. The SF-36 measures health-related quality of life
and consists of 36 items in total, and includes 2 subscales,
which are physical and mental. The subscales are scored
between 0 and 100 and a low score indicates poor health
status [22].
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2.3. Statistical analysis
All of the data were analyzed using IBM SPSS Statistics
for Windows 22.0 (IBM Corp., Armonk, NY, USA). The
normal distribution of the data was examined using the
Shapiro-Wilk test. Descriptive statistics were presented as
frequency and percentage (%) for the categorical variables
and the mean ± standard deviation according to the
distribution of the continuous variables. The independentsamples t test and chi square test (percentages, categorical
variables) were used for comparisons between 2 groups.
The correlation between the studied variables was
evaluated using the Pearson correlation coefficient. A type
I error level of 5% was accepted as statistically significant.
To obtain a power of 85% with a probability of a 2-tailed
type I error of 0.05, a sample of 35 participants was required
in each group to demonstrate a significant difference on
the FIS score [23]. Power analysis was calculated using
G*Power 3.1 (Heinrich Heine University Düsseldorf,
Düsseldorf, Northrhine-Westphalia, Germany) software.
3. Results
Participating in this study were 35 patients with SSc (6
males and 29 females, mean age of 50.71 ± 10.09 years)
and 35 healthy subjects (8 males and 27 females, mean age
of 54.14 ± 9.51 years). The mean disease duration was 7.64
± 5.38 years. The demographic and clinical characteristics
of the subjects are listed in Table 1. The healthy control
subjects were well-matched with the SSc group for age,
sex, and BMI (P > 0.05). The subjects who quit smoking at
least 9 months prior to the start of the study were included,
and there was no difference between the 2 groups in terms
of the number of former smokers and smoking history (P
> 0.05). Moreover, the participants did not have regular
exercise habits. Compared with the healthy control group,
the SSc group showed significantly higher pulmonary
symptoms (cough and sputum) and dyspnea severity (P
< 0.05). Of the patients, 20 (57.1%) had diffuse SSc and
15 (42.9%) had limited disease. Arthralgia and complaints
compatible with gastrointestinal disease were reported
by 14 (40.0%) and 10 (28.57%) of the patients with SSc,
respectively. Of the patients, 28% (80.0%) had Raynaud’s
syndrome and 5 (14.28%) had digital ulcerations.
The comparisons of the total and cognitive, physical,
and psychosocial subscale fatigue scores, pulmonary
function test results, diffusion capacity, and respiratory
muscle strength values of the between the SSc group
and healthy control group are shown in Table 2. The
SSc patients had significantly lower total and cognitive,
physical, and psychosocial subscale fatigue scores than
the controls (P < 0.001). Patients with SSc showed lower
FEV1%, FVC%, PEF%, DLCO%, MIP%, and MEP% (P <
0.05) than the controls, whereas there was no difference in
the FEV1/FVC% between the groups (P > 0.05).

YAKUT et al. / Turk J Med Sci
Table 1. Demographic and clinical characteristics of the patients with SSc and the healthy subjects.
SSc patients
(n = 35)

Healthy individuals
(n = 35)

P-value

Sex (male/female), n

6/29

8 / 27

0.550

Age (years)

50.71 ± 10.09

54.14 ± 9.51

0.369

Disease duration (years)

7.64 ± 5.38

-

-

Height (cm)

162.02 ± 7.55

166.34 ± 6.56

0.401

Weight (kg)

70.59 ± 15.59

76.42 ± 13.56

0.451

BMI (kg/m2)

26.10 ± 4.76

27.29 ± 3.84

0.599

Former smoker, n (%)

7 (20.0)

8 (22.8)

0.771

Smoking history (packet-years)

2.4 ± 6.09

2.25 ± 5.33

0.743

Diffuse SSc, n (%)

20 (57.1)

-

-

Limited SSc, n (%)

15 (42.9)

-

-

PH n (%)

14 (40.0)

-

-

18 (51.4)

-

-

Cough, n (%)

17 (48.5)

1 (2.8)

< 0.001

Sputum, n (%)

13 (37.1)

1 (12.8)

0.001

Dyspnea severity (mMRCS score)

2.60 ± 0.69

0.14 ± 0.35

< 0.001

Gastrointestinal symptom

Type of disease

ILD n (%)
Pulmonary symptom

10 (28.57)

-

-

Arthralgia

14 (40.0)

-

-

Digital ulcerations, n (%)

5 (14.28)

-

-

Raynaud’s syndrome, n (%)

28 (80.0)

-

-

Data are presented as the number, percentage, and/or the mean ± standard deviation; BMI: body mass
index; PH: pulmonary hypertension; ILD: interstitial lung disease; mMRCS: modified medical research
council scale.

The comparisons of the peripheral muscle strength,
functional capacity, and health-related quality of life
results of between the SSc group and healthy control
group are shown in Table 3. In addition, the results of the
subparameters of the HAQ-DI and SHAQ, evaluating the
disease-specific quality of life, are also indicated in Table 3
for the SSc group. The SSc patients exhibited significantly
weaker peripheral muscle strength and shorter walking
distance than the healthy controls (P < 0.05). The SSc
patients had significantly lower physical and mental
category scores on the SF-36 than the healthy controls (P
< 0.05).
Total fatigue in SSc group was significantly associated
with age, dyspnea severity, pulmonary function, diffusion
capacity, respiratory-peripheral muscle strength,
functional capacity, and health-related quality of life
(Table 4). Cognitive fatigue scores in the SSc group
were significantly associated with age, dyspnea severity,
handgrip and lower-limb muscle strength, functional

capacity, and health-related quality of life (SF-36, HAQ-DI,
and SHAQ) (P < 0.05). Physical fatigue scores in the SSc
group were significantly associated with dyspnea severity,
pulmonary function (FEV1%, FVC%, PEF%), DLCO,
MIP, MEP, handgrip and lower-limb muscle strength,
functional capacity, and health-related quality of life (SF36, HAQ-DI, and SHAQ) (P < 0.05). Psychosocial fatigue
scores in the SSc group were significantly associated with
dyspnea severity, MEP, handgrip and lower-limb muscle
strength, functional capacity, and health-related quality of
life (SF-36, HAQ-DI, and SHAQ) (P < 0.05).
4. Discussion
According to the results of the current study, 80% of the
SSc patients experienced fatigue, and the SSc patients
had higher total and cognitive, physical, and psychosocial
subscale scores of fatigue than the healthy controls.
Fatigue in the SSc group was significantly associated
with age, dyspnea severity, diffusion capacity, respiratory
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Table 2. Comparison of fatigue severity and pulmonary function, diffusion capacity, and respiratory
muscle strength in the patients with SSc and the healthy subjects.
SSc
patients (n = 35)

Healthy individuals
(n = 35)

P-value

Fatigue severity n (%)

28 (80.0)

6 (17.1)

<0.001

FIS total score

74.62 ± 31.54

11.05 ± 10.20

<0.001

FIS cognitive score

15.37 ± 7.84

5.65 ± 4.13

<0.001

FIS physical score

23.48 ± 8.36

4.37 ± 3.88

<0.001

FIS psychosocial score

35.77 ± 17.22

6.02 ± 4.55

<0.001

FVC (%pred)

76.82 ± 18.24

94.62 ± 6.86

<0.001

FEV1 (%pred)

78.08 ± 19.78

93.06 ± 5.15

<0.001

FEV1/FVC (%pred)

103.45 ± 8.39

95.34 ± 5.24

0.035

PEF (%pred)

74.57 ± 22.26

92.68 ± 11.17

<0.001

Pulmonary function test

DLCO (%pred)

61.88 ± 17.25

95.40 ± 6.73

<0.001

MIP cmH2O (%pred)

58.54 ± 31.33

99.03 ± 17.23

0.001

MEP cmH2O (%pred)

57.80 ± 23.18

116.42 ± 15.17

0.022

Data are presented as the number, percentage, and/or the mean ± standard deviation; FIS: Fatigue
Impact Scale; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; PEF: peak
expiratory flow; DLCO: diffusion capacity for carbon monoxide; MIP: maximal inspiratory pressure;
MEP: maximal expiratory pressure, %pred: percent predicted.

and peripheral muscle strength, functional capacity, and
health-related quality of life. Many studies have reported
that fatigue is very common in SSc patients, similar to
the results herein [10,24]. Sandusky et al. [25] reported a
prevalence of fatigue at 76% in SSc patients. Thus far, few
studies have fatigue correlations and predictors in patients
with SSc in a sufficiently broad and comprehensive
manner. Willems et al. [26] reported that fatigue was
associated with lung involvement, female sex, and low
coping and acceptance skills in patients with SSc. In
a study by Thombs et al. [5], it was stated that a higher
number of comorbidities, respiratory problems, smoking,
gastrointestinal symptoms, and depression were associated
with higher levels of fatigue in patients with SSc. Unlike
previous studies, in addition to the clinical features and
symptoms of patients, it is our belief that the current study
was more comprehensive, by examining the relationship
between fatigue and dyspnea severity, respiratoryperipheral muscle strength, functional capacity, and
health-related quality of life.
Due to lung involvement, poor ventilation distribution,
lung membrane thickening, and pulmonary capillary
bed loss can potentially lead to structural changes in
airways, resulting in a loss of air flow that can be reflected
by increased ventilator demand in SSc patients [27].
Therefore, the use of a spirometer and DLCO measurement
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is very common and important in the diagnosis and
follow-up of SSc patients [28]. Similar to other studies,
lower pulmonary function, DLCO, and respiratory muscle
strength was also observed in the patients with SSc when
compared to the controls [5,29]. In the current study,
fatigue showed a significant correlation with DLCO and
respiratory muscle strength, but not with pulmonary
functions. Thus, decreased respiratory muscle strength
and diffusion capacity increase fatigue severity, rather
than impair pulmonary functions in this population. It is
our belief that respiratory muscle strength measurement,
similar to DLCO, reflects the clinic of patients more than
the pulmonary function tests. Therefore, an evaluation of
respiratory muscle strength is recommended from the early
period in the diagnosis and follow-up of patients with SSc.
Moreover, when the subscales of fatigue are examined, it
can be seen that decreased pulmonary function, DLCO,
and respiratory muscle strength affected physical fatigue
more than cognitive and psychosocial fatigue.
It has been reported that skin-tightening limiting
movement and chest expansion, ILD, and PH may cause
dyspnea in SSc patients [5]. No comprehensive studies that
examined the relationship between fatigue and dyspnea
severity in SSc patients could be found in the literature.
However, the dyspnea severity, which was significantly
higher in the SSc patients than in the healthy controls in the
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Table 3. Comparison of the peripheral muscle strength, functional capacity, and health-related quality of life
results of the patients with SSc and the healthy subjects.
SSc patients
(n = 35)

Healthy individuals
(n = 35)

P-value

QF strength (kg)

6.84 ± 1.84

17.40 ± 5.46

<0.001

Handgrip (kg)

16.47 ± 3.77

36.35 ± 5.23

0.034

6MWT walking distance (m)

395.08 ± 75.00

546.34 ± 42.30

0.035

6MWT walking distance (%pred)

66.0 3 ± 10.85

98.07 ± 4.96

0.026

HAQ-DI

1.06 ± 0.60

-

-

SHAQ-Raynaud’s phenomenon VAS

1.32 ± 0.51

-

-

SHAQ-digital ulcer VAS

0.84 ± 0.49

-

-

SHAQ-digestive VAS

0.92 ± 0.45

-

-

SHAQ-pulmonary VAS

1.35 ± 0.73

-

-

SHAQ-overall disease severity VAS

1.47 ± 0.67

-

-

SHAQ-global

1.12 ± 0.54

-

-

SF-36 physical score

39.60 ± 18.38

82.77 ± 6.79

<0.001

SF-36 mental score

42.57 ± 15.20

80.51 ± 5.60

<0.001

Peripheral muscle strength

Functional capacity

Health-related quality of life

Data are presented as the mean ± standard deviation; QF: quadriceps femoris muscle; 6MWT: 6-Minute
Walking Test; HAQ-DI: Health Assessment Questionnaire Disability Index; SHAQ: Scleroderma Health
Assessment Questionnaire; VAS: visual analogue scale, SF-36: Short Form-36 Quality of Life Questionnaire.

current study, was correlated with the total and cognitive,
physical, and psychosocial subscale fatigue scores. As lung
involvement increases in the patients, the dyspnea severity
may increase, which may, in turn, limit the functionality
of the patients. Therefore, it is our belief that this indirectly
increased dyspnea severity may affect the level of
fatigue. For this reason, it should not be ignored that an
assessment of dyspnea, due to many different reasons, may
occur in this patient group and dyspnea severity reduction
strategies should be suggested in fatigue management.
Skeletal muscle involvement in SSc ranges from 24%
to 97%. Muscle involvement in the form of myositis or
noninflammatory myopathy in SSc patients causes general
weakness and muscle atrophy [30]. Hand grip strength can
be generalized as a global muscle strength marker in SSc.
However, strength loss rates differ in the upper and lower
extremities, with a greater decrease in muscle strength in
the lower extremities than in the upper extremities [31].
Therefore, an evaluation of both upper- and lower-limb
strength is important to reveal true peripheral muscle
weakness. The upper and lower-limb muscle strength of
the patients in the current study was lower than that in
the healthy controls, which was similar to the literature
[23,29]. Contrary to the correlation between fatigue and

upper-lower muscle strength, which was observed in the
current study, no studies that investigated the relationship
between general fatigue severity and peripheral muscle
strength could be found in the literature. In addition to the
upper-limb, the lower-limb muscle strength, which is one
of the determinants of functional capacity, decreases in
these patients and affects the severity of fatigue. This result
suggested that weakness and atrophy in both upper- and
lower-limb muscles may increase fatigue more quickly,
and approaches to maintain and increase peripheral
muscle strength can be effective in managing fatigue.
Similar to the findings herein, it was reported in other
studies that walking distance and its predicted value
decreased in SSc patients when compared to healthy
controls [4,19,29]. Changes in the small blood vessels of
the skeletal muscles due to vascular damage may also have
a negative effect on the oxygen supplied to the cells, which
contributes to weaker exercise performance and functional
capacity [32]. Deuschle et al. [4] investigated the 6MWT
and associated clinical parameters in patients with SSc and
found that the 6MWT was correlated with disease activity,
SHAQ score, nutrition status, age, hemoglobin values, and
several lung function parameters, but did not investigate
its relationship with fatigue. In the current study, in
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Table 4. Correlations between the fatigue severity and demographic data, dyspnea severity, pulmonary
function, peripheral muscle strength, functional capacity, functional disability, and health-related quality
of life of the SSc patients.
FIS
total

FIS
cognitive

FIS
physical

FIS
psychosocial

Age (years)

0.337*

0.355*

0.278

0.320

Disease duration (years)

0.071

0.152

0.004

0.059

BMI (kg/m2)

0.063

-0.082

0.141

0.084

Dyspnea severity (mMRCS score)

0.621**

0.595**

0.612**

0.570**

FVC (%pred)

–0.276

–0.238

–0.359*

–0.237

FEV1 (%pred)

–0.303

–0.236

–0.386*

–0.274

FEV1 / FVC (%pred)

0.056

–0.195

–0.047

–0.009

PEF (%pred)

–0.319

–0.203

–0.394*

–0.300

DLCO (%pred)

–0.352*

–0.321

–0.359*

–0.326

MIP (%pred)

–0.358*

–0.300

–.0385*

–0.332

MEP (%pred)

–0.375*

–0.324

–0.387*

–0.387*

Quadriceps strength (kg)

–0.407*

–0.372*

–0.400*

–0.382*

Handgrip strength (kg)

–0.403*

–0.348*

–0.503**

–0.347*

6MWT walking distance (m)

–0.509**

–0.369*

–0.491**

–0.526**

6MWT walking distance (%pred)

–0.379*

–0.374*

–0.439**

–0.444**

HAQ-DI

0.751**

0.699**

0.729**

0.704**

SHAQ-global

0.784**

0.715**

0.752**

0.745**

SF-36 physical score

–0.776**

–0.616**

–0.692**

–0.687**

SF-36 mental score

–0.712**

–0.710**

–0.708**

–0.754**

*0.01< P ≤0.05, **P ≤ 0.01, r: Pearson’s correlation coefficient.

addition to being related to total fatigue and functional
capacity in the SSc patients, the subscales of the FIS were
also evaluated, and it was determined that fatigue affected
both the cognitive and psychosocial states, as well as the
physical state, and they were correlated with functional
capacity. These results showed that individuals with more
social and cognitive fatigue may have lower functional
capacity, due to lower motivation and social involvement.
The patient sample herein had a mean HAQ-DI score
of ≥1.0, which was similar to that in other studies, and
this cut-off was important because it was associated with
high morbidity and mortality in this patient group over
a period of 4 years [33–35]. Also observed in the current
study was a correlation between the HAQ-DI and the
total and cognitive, physical, and psychosocial subscale
fatigue scores. Many studies have confirmed that fatigue
is one of the most important symptoms in SSc, which has
a significantly negative impact on the functional disability,
living, and quality of life of patients [35,36]. The mean
SHAQ score in the patient group was similar to that of
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other studies, while the SF-36 physical and mental scores
were significantly lower than those in the healthy group
[29,37,38]. In a study conducted by McNearney et al. [38],
fatigue was correlated with the physical component of
the SF-36 in SSc patients. Jacoub et al. [37] demonstrated
a strong association between fatigue and health-related
quality of life (all domains of the SF-36 and SHAQ) in SSc
patients, as in the current study. Fatigue severity increases
with a decrease in pulmonary functions and diffusion
capacities, increase in dyspnea severity, and decrease in
respiratory-peripheral muscle strength and functional
capacities. As a result of this, the daily life activities and
participation of patients are limited, and their quality of
life deteriorates. Therefore, adequate fatigue management
and related factors can lead to improvements in functional
disability, and ultimately, to a significant improvement in
the quality of life of these patients.
The strongest aspect of this study was that it was the first
comprehensive study to evaluate the total, and cognitive,
physical, and psychosocial aspects of fatigue, and examine
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their relationship with disease-related parameters in SSc
patients. This study had several limitations. First, the
influences of additional factors, possibly related to fatigue
in SSc patients, were not evaluated, such as inflammatory
cytokines, serum markers, and medication. Second,
this study was cross-sectional and in the study sample,
the results were not separated according to the type of
disease (diffuse or limited). Therefore, further research
is suggested to determine the effects of these additional
factors on fatigue in different types of SSc.
The results showed that SSc patients experienced
more frequent and severe fatigue when compared to the
healthy controls. Moreover, increased fatigue severity was
significantly associated with the age, dyspnea severity,
pulmonary function, diffusion capacity, respiratory
and peripheral muscle strength, functional capacity,
and health-related quality of life in the SSc population
herein. This suggested that fatigue severity in patients
with SSc is not solely associated with clinical features and
symptoms. Therefore, fatigue severity and these diseaserelated factors should be evaluated comprehensively in the
clinic. Moreover, in SSc patients, respiratory exercises and
respiratory muscle training for increased ventilation and
respiratory muscle strength; dyspnea reduction strategies
for decreased dyspnea; aerobic and resistant exercise
programs for increased peripheral muscle strength; daily

life activity training, and energy conservation techniques
can be recommended and applied from the early period in
fatigue management. As a result, the quality of life of the
patients and their participation in daily life activities can
be increased through fatigue management. In addition,
we believe that the results of this study support the need
for further research on fatigue and its related factors in
patients with SSc.
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